Enter your login e-mail to the account
Search
Search parameters
Search results
- CURRENT RESISTENCY OF PATHOGENS OF THE UPPER RESPIRATORY TRACT
doc. MUDr. Anna Líšková, PhD.
(12/2005, clearly ) - Spotreba antibiotík predpísaných na lekársky predpis v roku 2003
MUDr. Ružena Rolná, MPH, Mgr. Marián Gežo
(4/2004, Topic ) - PAIN AND NEUROPATHY
MUDr. Pavol Kučera, PhD.
(12/2006, clearly ) - IT IS POSSIBLE TO AWAIT FROM „DISEASE MANAGEMENT PROGRAM“ PROFESSIONAL, ECONOMICAL PROFITABLY CARE OF DIABETICS 2. TYPE?
doc. MUDr. Boris Krahulec, CSc., Dr. med. Valerien Sulik
(10/2007, Spectrum ) - Liekové knižky
JUDr. MUDr. Peter Kováč, PhD.
(1/2006, Paragraph )
- Správa o XXXI. Slovensko-českom neurovaskulárnom sympóziu v Bratislave
MUDr. Róbert Garay, CSc.
(5/2003, Comments )
- Pneumococcal infections in children and the prevention
MUDr. Peter Čižnár, CSc.
(5/2009, Review articles )
- PHARMACOECONOMICS – ITS POSITION IN DRUG POLICY
prof. MUDr. Jozef Holomáň, CSc.
(1/2008, Review articles ) - PHARMACOECONOMICS – ITS POSITION IN DRUG POLICY
prof. RNDr. Viliam Foltán, CSc., Mgr. Veronika Dubajová, PharmDr. Tomáš Tesař, PHD, MBA
(1/2008, Review articles ) - PHARMACOECONOMICS OF ONCOLOGIC TREATMENT FORM THE POINT OF VIEW OF HEALTH INSURANCE COMPANY
MUDr. Alexander Paluch, MUDr. Lucia Vitárius, MPH
(1/2008, Review articles ) - Health technology assessment and value for money in drug policy
PharmDr. Martin Višňanský, MBA, PhD., MSc., Mgr. Radoslav Suchovič
(2/2017, Main topic ) - Criteria of the oncology drugs categorisation process on use of the principle „the value for money“ from the point of view of expected benefits
MVDr., Mgr. Peter Mrva, MPH
(2/2017, Main topic ) - Použitie rastových faktorov myelopoézy v profylaxii febrilnej neutropénie
MUDr. Juraj Chudej, PhD., MUDr. Matej Hrnčár, MUDr. Juraj Sokol, PhD., MUDr. Ivana Plameňová, PhD., MUDr. Ľubica Váleková, PhD., Prof. MUDr. Ján Staško, PhD.
(2/2018, Review articles ) - Impact of pricing regulations on access to innovative therapies
Tím Asociácie inovatívneho farmaceutického priemyslu Slovakia, Bratislava
(1/2020, Main topic ) - The aim of QALY in the assessment of cost – effectiveness in oncologic treatment
doc. MUDr. Ján Bielik, CSc., MUDr. Elena Marušáková, MBA
(1/2020, Main topic )
- Quo vadis, štátna lieková politika?
Doc. PharmDr. Tomáš Tesař, PhD., MBA, MPH, MSc (HTA)
(1/2021, Editorial ) - Biological drugs from the perspective of pharmacy
PharmDr. Katarína Bruchatá, PhD., Mgr. Peter Heinz
(4/2014, Pharmaceutical technology ) - Trends in consumption of drugs for respiratory system in the Slovak Republic
Doc. PharmDr. Tomáš Tesař, PhD., MPH, MBA, MSc (HTA), PharmDr. Ľubica Lehocká, PhD., PharmDr. Lucia Masaryková, PhD.
(1/2018, Clinical pharmacy ) - Quo vadis, štátna lieková politika?
Doc. PharmDr. Tomáš Tesař, PhD., MBA, MPH, MSc (HTA)
(1-2/2020, Editorial ) - Trends in consumption of drugs from the ATC group Ophthalmologicals in the Slovak Republic
Doc. PharmDr. Tomáš Tesař, PhD., MPH, MBA, MSc (HTA), PharmDr. Ľubica Lehocká, PhD., PharmDr. Lucia Masaryková, PhD.
(4/2018, Clinical pharmacy ) - Trends in consumption of drugs based on defined daily doses in the Slovak republic
Doc. PharmDr. Tomáš Tesař, PhD., MPH, MBA, MSc (HTA), PharmDr. Ľubica Lehocká, PhD., PharmDr. Lucia Masaryková, PhD.
(4/2017, Clinical pharmacy ) - Analysis of consumption of drugs from the ATC group Nervous system in the Slovak Republic
doc. PharmDr. Tomáš Tesař, PhD., MPH, MBA, MSc (HTA), PharmDr. Ľubica Lehocká, PhD., PharmDr. Lucia Masaryková
(3/2018, Clinical pharmacy ) - Analysis of drug consumption development from 2009 to 2018 in the Slovak Republic
doc. PharmDr. Tomáš Tesař, PhD., MPH, MBA, MSc (HTA), PharmDr. Ľubica Lehocká, PhD., PharmDr. Lucia Masaryková, PhD.
(1/2019, Editorial ) - Analýza spotreby liekov z ATC skupiny Tráviaci trakt a metabolizmus v podmienkach Slovenskej republiky
Doc. PharmDr. Tomáš Tesař, PhD., MPH, MBA, MSc (HTA), PharmDr. Ľubica Lehocká, PhD., PharmDr. Lucia Masaryková, PhD.
(2/2018, Clinical pharmacy )